EGFR and lung cancer: Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are the standard treatment for non‐small cell lung cancer (NSCLC) with EGFR activating mutations (e.g., Ex19del or L858R).1, 2